Related Experiment Video
Updated: Dec 27, 2025

A Robust Discovery Platform for the Identification of Novel Mediators of Melanoma Metastasis
Published on: March 8, 2022
The Engagement Between MDSCs and Metastases: Partners in Crime
Rosalinda Trovato1, Stefania Canè1, Varvara Petrova1
1Section of Immunology, Department of Medicine, University of Verona, Verona, Italy.
Abstract:
Tumor metastases represent the major cause of cancer-related mortality, confirming the urgent need to identify key molecular pathways and cell-associated networks during the early phases of the metastatic process to develop new strategies to either prevent or control distal cancer spread. Several data revealed the ability of cancer cells to establish a favorable microenvironment, before their arrival in distant organs, by manipulating the cell composition and function of the new host tissue where cancer cells can survive and outgrow. This predetermined environment is termed "pre-metastatic niche" (pMN). pMN development requires that tumor-derived soluble factors, like cytokines, growth-factors and extracellular vesicles, genetically and epigenetically re-program not only resident cells (i.e., fibroblasts) but also non-resident cells such as bone marrow-derived cells. Indeed, by promoting an "emergency" myelopoiesis, cancer cells switch the steady state production of blood cells toward the generation of pro-tumor circulating myeloid cells defined as myeloid-derived suppressor cells (MDSCs) able to sustain tumor growth and dissemination. MDSCs are a heterogeneous subset of myeloid cells with immunosuppressive properties that sustain metastatic process. In this review, we discuss current understandings of how MDSCs shape and promote metastatic dissemination acting in each fundamental steps of cancer progression from primary tumor to metastatic disease.
Insights
Cancer cells create pre-metastatic niches (pMNs) by reprogramming host tissues. Myeloid-derived suppressor cells (MDSCs) are key players in this process, promoting tumor growth and spread.
Area of Science:
- Oncology
- Cancer Metastasis Research
- Immunology
Background:
- Tumor metastases are the primary cause of cancer mortality, necessitating research into early metastatic pathways.
- Cancer cells manipulate host tissues to form pre-metastatic niches (pMNs) for survival and growth.
- pMNs are established by tumor-derived factors that reprogram resident and non-resident cells.
Purpose of the Study:
- To review the role of myeloid-derived suppressor cells (MDSCs) in shaping and promoting metastatic dissemination.
- To discuss how MDSCs contribute to each stage of cancer progression, from primary tumor to distal metastasis.
Main Methods:
- This review synthesizes current understanding from existing scientific literature.
- Analysis of data on tumor-derived factors, cellular reprogramming, and immune cell function.
Main Results:
- Tumor cells induce "emergency" myelopoiesis, generating pro-tumorigenic circulating myeloid cells.
- Myeloid-derived suppressor cells (MDSCs) are a heterogeneous, immunosuppressive cell subset crucial for metastasis.
- MDSCs sustain tumor growth and dissemination by influencing the pre-metastatic niche.
Conclusions:
- MDSCs play a critical role in facilitating tumor metastasis at multiple stages.
- Targeting MDSCs and their functions in the pre-metastatic niche may offer new therapeutic strategies.
- Understanding MDSC-mediated immune suppression is vital for controlling cancer spread.
More Related Videos
11:15A Preclinical Mouse Model of Osteosarcoma to Define the Extracellular Vesicle-mediated Communication Between Tumor and Mesenchymal Stem Cells
Published on: May 6, 2018
09:30Mesenchymal Stem Cell Isolation from Pulp Tissue and Co-Culture with Cancer Cells to Study Their Interactions
Published on: January 7, 2019
Related Concept Videos
Metastasis
Epithelial-to-Mesenchymal Transition
The epithelial-to-mesenchymal transition or EMT is a developmental process commonly observed in wound healing, embryogenesis, and cancer metastasis. EMT is induced by transforming growth factor-beta (TGF-β) or receptor tyrosine kinase (RTK) ligands, which further...
The Tumor Microenvironment